0001552781-16-001651.txt : 20160513 0001552781-16-001651.hdr.sgml : 20160513 20160513155556 ACCESSION NUMBER: 0001552781-16-001651 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160513 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160513 DATE AS OF CHANGE: 20160513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xtant Medical Holdings, Inc. CENTRAL INDEX KEY: 0001453593 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205313323 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34951 FILM NUMBER: 161648193 BUSINESS ADDRESS: STREET 1: 664 CRUISER LANE CITY: BELGRADE STATE: MT ZIP: 59714 BUSINESS PHONE: 406-388-0480 MAIL ADDRESS: STREET 1: 664 CRUISER LANE CITY: BELGRADE STATE: MT ZIP: 59714 FORMER COMPANY: FORMER CONFORMED NAME: Bacterin International Holdings, Inc. DATE OF NAME CHANGE: 20100615 FORMER COMPANY: FORMER CONFORMED NAME: K KITZ INC DATE OF NAME CHANGE: 20090108 8-K 1 e00316_xtnt-8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 13, 2016

 

Xtant Medical Holdings, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-34951 20-5313323
(Commission File Number) (IRS Employer Identification No.)

 

664 Cruiser Lane  
Belgrade, Montana 59714
(Address of Principal Executive Offices) (Zip Code)

 

(406) 388-0480

(Registrant’s Telephone Number, Including Area Code)

 

Not applicable 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

Item 7.01     Regulation FD Disclosure.

  

The Company issued a press release entitled “Xtant Medical Sets Annual Meeting and Record Dates” which is attached as Exhibit 99.1 and incorporated herein.

 

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.  

 

Item 9.01.     Financial Statements and Exhibits.

 

(d)     Exhibits.

 

Exhibit No.     Description
     
99.1   Press Release dated May 13, 2016 entitled “Xtant Medical Sets Annual Meeting and Record Dates”

 

 
 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  May 13, 2016  
  XTANT MEDICAL HOLDINGS, INC.
   
  By:  /s/ John Gandolfo
  Name:  John Gandolfo
  Title:  Chief Financial Officer

 

 
 

EXHIBIT INDEX

 

Exhibit No.     Description
     
99.1   Press Release dated May 13, 2016 entitled “Xtant Medical Sets Annual Meeting and Record Dates”

 

 

EX-99.1 2 e00316_ex99-1.htm

 

Xtant Medical Sets Annual Meeting and Record Dates

 

 

BELGRADE, Mont., May 13, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, has established a record date for its 2016 annual meeting of stockholders.

 

Xtant Medical stockholders of record at the close of business on May 23, 2016 will be entitled to notice of the annual meeting and to vote upon matters considered at the meeting. The annual meeting is scheduled to be held at Hilton Garden Inn, Dayton South/Austin Landing, 12000 Innovation Drive, Dayton, Ohio 45342 at 8:00 a.m. Eastern Time on June 15, 2016.

 

Xtant Medical will make available to all stockholders of record important information about the meeting and the matters to be considered. Stockholders are urged to review that information when it becomes available.

 

About Xtant Medical Holdings, Inc.

 

Xtant Medical Holdings, Inc. (NYSE MKT:XTNT) is a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.

 

Important Cautions Regarding Forward-looking Statements

 

This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “continue,” “efforts,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “projects,” “forecasts,” “strategy,” “will,” “goal,” “target,” “prospects,” “potential,” “optimistic,” “confident,” “likely,” “probable” or similar expressions or the negative thereof..

 

Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: our ability to integrate the acquisition of X-spine Systems, Inc. and any other business combinations or acquisitions successfully; our ability to remain listed on the NYSE MKT; our ability to obtain financing on reasonable terms; our ability to increase revenue; our ability to comply with the covenants in our credit facility; our ability to maintain sufficient liquidity to fund our operations; the ability of our sales force to achieve expected results; our ability to remain competitive; government regulations; our ability to innovate and develop new products; our ability to obtain donor cadavers for our products; our ability to engage and retain qualified technical personnel and members of our management team; the availability of our facilities; government and third-party coverage and reimbursement for our products; our ability to obtain regulatory approvals; our ability to successfully integrate recent and future business combinations or acquisitions; our ability to use our net operating loss carry-forwards to offset future taxable income; our ability to deduct all or a portion of the interest payments on the notes for U.S. federal income tax purposes; our ability to service our debt; product liability claims and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; our ability to obtain and protect our intellectual property and proprietary rights; infringement and ownership of intellectual property; our ability to remain accredited with the American Association of Tissue Banks; influence by our management; our ability to pay dividends; our ability to issue preferred stock; and other factors..

 

 
 

Additional risk factors are listed in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading “Risk Factors.” You should carefully consider the trends, risks and uncertainties described in this document, the Form 10-K and other reports filed with or furnished to the SEC before making any investment decision with respect to our securities. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline, and you could lose all or part of your investment. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

 

Contact:

COCKRELL GROUP

877.889.1972

investorrelations@thecockrellgroup.com

cockrellgroup.com

 

Company Contact:

Molly Mason

406.388.0480

 

 

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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